Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally active, direct-acting P2Y12 receptor antagonist used to prevent thrombotic events.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
* Prevention of stent thrombosis in patients who have undergone percutaneous coronary intervention (PCI).
## Adult Dosing
* **ACS:** Loading dose of 180 mg orally once, followed by 90 mg orally twice daily.
* **Post-PCI:** Generally 90 mg orally twice daily. Duration of therapy depends on clinical indication and bleeding risk, often guided by local protocols.
* **Patients with a history of MI:** 60 mg orally twice daily.
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment needed for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment needed for mild to moderate renal impairment. Use with caution in severe renal impairment.
## Contraindications
* Active pathological bleeding.
* History of intracranial hemorrhage.
* Hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
The most common and serious adverse effect is bleeding (including life-threatening and fatal bleeding). Other adverse effects include dyspnea, bradycardia, and hyperuricemia.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure. Coadministration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor exposure.
* **CYP3A4 Substrates (Moderate Inhibitor):** Ticagrelor may increase plasma concentrations of drugs metabolized by CYP3A4 (e.g., simvastatin, atorvastatin). Use caution and consider lower doses of the coadministered drug.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Concurrent use should be carefully considered and monitored.
* **Aspirin:** Generally coadministered with aspirin; however, higher doses of aspirin may reduce the efficacy of ticagrelor. Doses of aspirin above 100 mg are not recommended.
* **NSAIDS:** Increased risk of bleeding. Avoid if possible.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for dyspnea.
* Monitor electrolytes, particularly potassium.
## Clinical Pearls
* Ticagrelor's onset of action is rapid.
* Discontinuation of ticagrelor prematurely increases the risk of thrombotic events.
* Patients experiencing dyspnea should be evaluated to rule out other causes.
* Ticagrelor is a direct-acting P2Y12 inhibitor and does not require metabolic activation, unlike clopidogrel.
***
*This information is intended for healthcare professionals and does not replace professional medical advice. Always consult the current prescribing information and relevant guidelines for complete and up-to-date details.*
